Key regions: France, India, United Kingdom, South Korea, Japan
Namibia, a country in southern Africa, has a small but growing market for Multiple Sclerosis (MS) Drugs.
Customer preferences: The demand for MS drugs in Namibia is driven by the increasing prevalence of MS in the country. MS is a chronic autoimmune disease that affects the central nervous system, and its prevalence in Namibia is on the rise. As a result, there is a growing need for effective treatments to manage the symptoms of the disease. Patients in Namibia generally prefer drugs that are affordable and have minimal side effects.
Trends in the market: The MS drugs market in Namibia is expected to grow steadily over the next few years. This growth can be attributed to several factors, including the increasing prevalence of MS in the country, the availability of more effective drugs, and the growing awareness of the disease among healthcare professionals and patients. There is also a trend towards the use of more advanced therapies, such as biologics and disease-modifying therapies, which are becoming more widely available in the country.
Local special circumstances: Namibia has a small and underdeveloped healthcare system, which presents several challenges for the MS drugs market. These challenges include a lack of healthcare infrastructure, limited access to healthcare services in rural areas, and a shortage of healthcare professionals. Additionally, the high cost of MS drugs can be a barrier to access for many patients, particularly those who are uninsured or underinsured.
Underlying macroeconomic factors: Namibia is a lower-middle-income country with a relatively small economy. Despite this, the country has made significant progress in improving healthcare outcomes in recent years. The government has invested in healthcare infrastructure and services, and there has been a growing focus on improving access to healthcare for all citizens. However, the country still faces significant challenges in terms of poverty, inequality, and unemployment, which can impact the affordability and accessibility of healthcare services, including MS drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
